Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BloodPril
- Development stage
- Unknown
- Lead developer
- Instituto Experience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BloodPril is an oral dietary supplement formulated to support healthy blood pressure, cardiovascular wellness, and normal blood circulation. It features a proprietary 500 mg blend of three amino acid compounds: L-arginine hydrochloride (L-Arginine HCl), L-arginine alpha-ketoglutarate (AAKG), and L-citrulline malate. These ingredients act as precursors in the nitric oxide pathway, promoting the synthesis of nitric oxide by endothelial nitric oxide synthase (eNOS). Nitric oxide induces the relaxation of vascular smooth muscle cells, leading to vasodilation, improved blood flow, and enhanced vascular elasticity.
- Brand names
- BloodPril
- Other names
- Blood Pril
02
Targets
NO2- (Nitrite)sGC (Soluble Guanylyl Cyclase)NOS3 (eNOS)
Beyond the preview
Go deeper on BloodPril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BloodPril.